- Repligen strikes $1.5B BioLife buyout to bag cell therapy product pharmas rely onTop-selling cell therapies from BMS, J&J and Gilead depend on a BioLife product, positioning Repligen to use the takeover to increase its exposure to the modality.BioSpace · 5d ago↗ source
- Summit counters PD-1/VEGF skeptics; Celldex drug fails skin disease study<figure><div><img src="https://imgproxy.divecdn.com/idsdMAHsPbXObDUtQW2qRG7uveBUVv6HCTn9NTtlDOI/g:nowe:0:0/c:1207:682/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0x…BioPharma Dive · 5d ago↗ source
- 6 companies hiring in Cambridge nowLooking for a biopharma job in Cambridge? Roles posted on BioSpace have more than doubled compared to last year.BioSpace